Table 5. Hemoglobin Levels Before and After Preoperative Iron Therapy.
| Author | Iron | EPO | Hb |
Other significant hematologic findings | |||
|---|---|---|---|---|---|---|---|
| Baseline | Pre-op | Post-op | Follow-up | ||||
| Cladellas et al, 2012 [32] | IV | IV | 11.2 ± 1 | 12.6 ± 0.9* | - | - | |
| Historic observation | Historic observation | 10.9 ± 0.9 | 10.9 ± 0.9 | - | - | ||
| Urena et al, 2017 [34] | IV iron sucrose 200 mg at days 10 and 1 | Subcutaneous 0.75 µg/kg | 10.7 ± 1.2 | 10.9 ± 1.2* | 9.4 ± 1.6 (discharge) | - | No significant difference between pre-op, post-op, or discharge Hb after intervention |
| Placebo | Placebo | 11.3 ± 1.6 | 11.1 ± 1.2* | 9.9 ± 1.6 | - | ||
| Johansson et al, 2015 [36]a | IV | None | 14.3 | - | 10.2 (POD 5) | 12.4** (POD 28) | More non-anemic on follow-up |
| Placebo | 14 | - | 10.5 | 11.6** | |||
| Padmanabhan et al, 2018 [35] | IV | None | 8.9 | 9.8 | - | - | Increase in ferritin, decrease in EPO, TSAT |
| Oral | 11.1 | 12 | - | - | |||
| Garrido-Martin et al, 2012 [33] | IV | None | 14 ± 1.63 | 12.7 ± 1.64 | 11.1 ± 1.52 (POD 10) | 12.7 ± 1.40 (POD 30) | Higher ferritin |
| Oral | 13.7 ± 1.46 | 12.6 ± 1.70 | 11.0 ± 1.28 | 12.4 ± 1.27 | |||
| Placebo | 14 ± 1.35 | 12.8 ± 1.29 | 11.0 ± 1.44 | 12.3 ± 1.15 | |||
| Spahn et al, 2019 [37] | IV | Subcutaneous 40,000 units | 12.8 ± 1.5 | - | 9.2*** (POD 5) | 9.1*** (POD 7) | Higher reticulocyte count |
| Placebo | 12.9 ± 15 | - | 8.7*** | 8.5*** | |||
*P < 0.05 between groups; **P < 0.05 from baseline; ***P < 0.001 between groups; aSD not reported. EPO: erythropoietin; Hb: hemoglobin; IV: intravenous; pre-op: preoperatively; POD: postoperative day; post-op: post-operatively; TSAT: transferrin saturation; SD: standard deviation.